ProSiteHunter: A Unified Framework for Sequence‐Based Prediction of Protein‐Nucleic Acid and Protein‐Protein Binding Sites
Advanced Science · 2026
DOI: 10.1002/advs.75931 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Dongliang Hou und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Information Engineering, Zhejiang University of Technology, HangZhou, China. Hauptthemen laut MEDLINE: Proteins, Computational Biology, Software, DNA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Nature Science Foundation of China, "Pioneer" and "Leading Goose" R&D Program of Zhejiang.
Abstract (Originalsprache)
Accurate identification of protein binding sites is essential for elucidating protein function, decoding molecular recognition, and guiding drug design. However, existing sequence‐based approaches are often designed for specific binding‐site types and therefore lack generality, whereas structure‐based methods typically rely on high‐quality structural models, limiting their applicability. Here, we present ProSiteHunter, a unified sequence‐based framework for predicting protein binding sites spanning protein‐DNA, protein‐RNA, protein‐protein, and antibody‐antigen interfaces. ProSiteHunter integrates the fine‐tuned protein language model SiteT5 with evolutionary, geometric, and statistical features extracted from sequences. These representations are further processed through a Multi‐Source Feature Fusion (MSFF) module, which captures bidirectional semantics, local associations, and global dependencies to achieve a comprehensive characterization of binding sites, thereby substantially improving predictive accuracy and generalization capability. Across comprehensive benchmarks, ProSiteHunter achieved a 38.4% average improvement in the area under the precision‐recall curve (PRAUC) for protein‐DNA/RNA/protein tasks and a 15.1% PRAUC enhancement on the particularly challenging antibody‐antigen task over state‐of‐the‐art methods. Moreover, ProSiteHunter is capable of identifying local flexible sites that complement AlphaFold3 predictions and improving the accuracy of antibody‐antigen interaction prediction. These results highlight ProSiteHunter as an efficient and unified approach for accurate and robust prediction of diverse protein binding sites.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Information Engineering, Zhejiang University of Technology, HangZhou, China.
- State Key Laboratory of Advanced Drug Delivery and Release Systems and Innovation Institute for AI in Medicine, College of Pharmaceutical Sciences, Zhejiang University, HangZhou, China.
ORCID-Profile: Zhan Zhou, Xiaogen Zhou, Guijun Zhang
Förderung
- National Key R&D Program of China
- National Nature Science Foundation of China
- "Pioneer" and "Leading Goose" R&D Program of Zhejiang
- Zhejiang Province High-level Talent Special Support Program
- Fundamental Research Funds for the Provincial Universities of Zhejiang
Zitieren
APA
Hou, D., Zhen, Q., Lv, Z., Cui, X., Wang, S., Hou, M., Zhou, Z., Zhou, X., & Zhang, G. (2026). ProSiteHunter: A Unified Framework for Sequence‐Based Prediction of Protein‐Nucleic Acid and Protein‐Protein Binding Sites. Advanced Science. https://doi.org/10.1002/advs.75931
Vancouver
Hou D, Zhen Q, Lv Z, Cui X, Wang S, Hou M, et al. ProSiteHunter: A Unified Framework for Sequence‐Based Prediction of Protein‐Nucleic Acid and Protein‐Protein Binding Sites. Advanced Science. 2026. doi:10.1002/advs.75931
BibTeX
@article{Hou2026,
author = {Hou, Dongliang and Zhen, Qihang and Lv, Zexin and Cui, Xinyue and Wang, Suhui and Hou, Minghua and Zhou, Zhan and Zhou, Xiaogen and Zhang, Guijun},
title = {ProSiteHunter: A Unified Framework for Sequence‐Based Prediction of Protein‐Nucleic Acid and Protein‐Protein Binding Sites},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.75931}
}
EUVIMED